Epithalon vs Rapamycin
Which Is Right for You? Complete Comparison (2026)
Epithalon vs Rapamycin comparison — telomerase-focused vs mTOR-focused anti-aging mechanisms, peptide vs small molecule, longevity evidence.
Epithalon vs Rapamycin: At a Glance
- ✓Synthetic tetrapeptide (Ala-Glu-Asp-Gly) pineal bioregulator
- ✓Activates telomerase and promotes telomere elongation in somatic cells
- ✓Regulates melatonin secretion and circadian rhythm
- ✓Extended lifespan and delayed tumor incidence in animal models
- ✓Developed by Prof. Khavinson at the St. Petersburg Institute of Bioregulation
- ✓mTOR inhibitor — suppresses cellular growth and proliferation pathways
- ✓FDA-approved immunosuppressant for organ transplant rejection
- ✓Extended lifespan 9-14% in NIA Interventions Testing Program mice
- ✓Improves immune function at low intermittent doses (Mannick 2014)
- ✓Most-studied pharmacological longevity intervention
Detailed Comparison
| Feature | Epithalon | Rapamycin |
|---|---|---|
| Mechanism | Synthetic tetrapeptide (pineal gland bioregulator) | mTOR inhibitor / immunosuppressantBest |
| Dosing | 5-10 mg SC daily for 10-20 day cycles | 2-6 mg weekly (longevity protocol — off-label) |
| Administration | Subcutaneous injection | Oral |
| Half-life | Short — rapid degradation (administered in cycles) | ~62 hours |
| FDA Status | Not FDA-approved — research peptide | FDA-approved (Rapamune — immunosuppression) |
| Key Trial | Khavinson VK et al. Bull Exp Biol Med 2003 — telomerase activation | Harrison DE et al. Nature 2009 — lifespan extension in mice |
| Side Effects | Injection site irritation; limited side effect data in humans | Immunosuppression at high doses, mouth sores, lipid elevation, insulin resistance |
Which Should You Choose?
Epithalon (Epitalon) (synthetic tetrapeptide (pineal gland bioregulator)) and Rapamycin (Sirolimus) (mtor inhibitor / immunosuppressant) serve different clinical roles despite both being in the Longevity peptide space. Epithalon (Epitalon) synthetic version of epithalamin that activates telomerase, promotes telomere elongation, and regulates melatonin production from the pineal gland. Rapamycin (Sirolimus) macrolide compound that inhibits mtor (mechanistic target of rapamycin), reducing cellular growth signaling.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Epithalon and Rapamycin
Choosing between Epithalon and Rapamycin depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Epithalon and Rapamycin is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Epithalon vs Rapamycin: Frequently Asked Questions
Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide that activates telomerase to lengthen telomeres and has shown lifespan extension and cancer reduction in Russian animal studies. Rapamycin is an mTOR inhibitor that mimics caloric restriction signaling and extends lifespan in mice by 25%+ (NIH ITP). They operate via completely different mechanisms and can theoretically complement each other in a combined anti-aging stack.
Rapamycin has stronger Western longevity evidence — it extends lifespan in multiple species, is validated by the NIH Interventions Testing Program, and has extensive mechanistic data. Epithalon has primarily Russian research data showing telomere lengthening, cancer reduction, and longevity effects in animal models, but lacks large Western ITP-style replication.
Many longevity practitioners use both — Epithalon for twice-yearly 10-day telomerase activation cycles (5–10 mg/day SC) and Rapamycin for weekly mTOR inhibition (3–6 mg weekly). Their mechanisms are complementary: Epithalon addresses replicative senescence via telomere maintenance while Rapamycin reduces mTORC1-driven cellular aging.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Epithalon or Rapamycin in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
